Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

Lantheus Medical Imaging announces the launch of ABLAVAR

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced the launch of ABLAVAR™ (gadofosveset trisodium), a unique, injectable MRA imaging agent used to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD).

20 Jan 2010

TUM biophysicists map changes in energy landscape of zipper-like protein molecule

Biophysicists at TUM, the Technische Universitaet Muenchen, have published the results of single-molecule experiments that bring a higher-resolution tool to the study of protein folding. How proteins arrive at the three-dimensional shapes that determine their essential functions - or cause grave diseases when folding goes wrong - is considered one of the most important and least understood questions in the biological and medical sciences.

20 Jan 2010

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

PTC Therapeutics, Inc. (PTC) today announced the initiation of an additional clinical trial of ataluren (PTC124®) in boys and young men with nonsense mutation Duchenne/Becker muscular dystrophy (nmDBMD) who have permanently lost the ability to walk independently.

20 Jan 2010

One of Cystic Fibrosis Foundation's active volunteers to carry Olympic Torch in Calgary

One of the Cystic Fibrosis Foundation's most active volunteers will carry the Olympic Torch today in Calgary as it makes its way to Vancouver for the Opening Ceremony of the 2010 Olympic Winter Games.

19 Jan 2010

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

A team of University of British Columbia researchers has identified fat-producing cells that possess "dual-personalities" and may further the development of treatments for muscle diseases such as muscular dystrophy and fibrosis.

19 Jan 2010

Flexpoint to develop infant bed cover using patented Bend Sensor® design

Flexpoint Sensor Systems, Inc. announced that they are working on the development of an infant bed cover using their patented Bend Sensor® design. The mattress will be used to monitor infants in the prevention of sudden infant death syndrome (“SIDS”).

18 Jan 2010

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Regulus Therapeutics Inc. today announced that new pre-clinical data from multiple therapeutic programs were presented at the “RNA Silencing: Mechanism, Biology and Application” Keystone Symposium held January 14 – 19, 2010 in Keystone, Colorado. Regulus and its collaborators presented data showing microRNA target regulation by anti-miRs, as well as data from therapeutic programs focused on oncology, immune disease and hepatitis C virus (HCV) infection.

18 Jan 2010

Scientists discover new links between inherited blindness and AHI1 gene

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine have discovered new links between a common form of inherited blindness affecting children and a gene known as Abelson helper integration site-1 (AHI1).

18 Jan 2010

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

Aeolus Pharmaceuticals, Inc. announced today that after review of the Company’s white paper on development of AEOL-10150 as a countermeasure for the lung effects of acute radiation syndrome, the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Radiological and Nuclear (CBRN) Countermeasures has informed the Company that, after careful analysis and consideration, it has invited Aeolus to submit a full proposal for a contract to develop AEOL 10150 from its current level of technical readiness to FDA approval.

13 Jan 2010

NIH awards 12 research grants totaling $5 million for Tβ4 research

REGENERX BIOPHARMACEUTICALS, INC. announced today that National Institutes of Health (NIH) has awarded 12 research grants totaling over $5,000,000 for the study of Tβ4 in 2009/2010. Many of these grants will be going to collaborators with whom RegeneRx is working to understand its numerous biological activities and capabilities in medical indications, including the role of Tβ4 as an anti-inflammatory agent in tissue regeneration and its promotion of stem cell maturation.

13 Jan 2010

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Immune cells causes inflammation in thyroid-associated ophthalmopathy

A cell type that causes significant scarring in lung disease appears to have a similar effect in Graves' disease, University of Michigan Health System researchers have found. The cells, called fibrocytes, are present at a higher than normal frequency in patients with Graves' disease, according to a new study, the first to associate fibrocytes with this autoimmune disease.

9 Jan 2010

Fibrocytes associated with Graves' disease

9 Jan 2010

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50 million. Scientists and clinicians at The University of Texas Health Science Center at Houston can address the diagnosis and treatment of these conditions, as well as the latest advances in research.

8 Jan 2010

CLSI’s document provides revised guidelines for screening cystic fibrosis

Clinical and Laboratory Standards Institute (CLSI) recently published Sweat Testing: Sample Collection and Quantitative Chloride Analysis; Approved Guideline—Third Edition (C34-A3). This document addresses appropriate methods of collection and analysis, quality control, and the evaluation and reporting of sweat test results for the diagnosis of cystic fibrosis.

7 Jan 2010

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

A recent study by doctors from the Hospital Cl-nic in Barcelona, Spain determined that repeated liver stiffness measurements (LSM) in the first year following liver transplant (LT) could discriminate between slow and rapid "fibrosers" (patients with fibrosis stage of F2-F4 one year post LT).

6 Jan 2010

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Excaliard Pharmaceuticals, Inc. announced today the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders.

6 Jan 2010

Increased coffee consumption linked to reduced hepatic fibrosis

Researchers from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) determined that patients with chronic hepatitis C virus (HCV) who consumed more than 308 mg of caffeine daily had milder liver fibrosis. The daily amount of caffeine intake found to be beneficial is equivalent to 2.25 cups of regular coffee.

5 Jan 2010

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Johns Hopkins University researchers have created biodegradable nanosized particles that can easily slip through the body's sticky and viscous mucus secretions to deliver a sustained-release medication cargo.

5 Jan 2010

Fibrosis News and Research

Further Reading

Lantheus Medical Imaging announces the launch of ABLAVAR

TUM biophysicists map changes in energy landscape of zipper-like protein molecule

PTC Therapeutics initiates additional clinical trial of ataluren in boys and young men with nmDBMD

One of Cystic Fibrosis Foundation's active volunteers to carry Olympic Torch in Calgary

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

Flexpoint to develop infant bed cover using patented Bend Sensor® design

Regulus Therapeutics presents new data on oncology, immune disease and HCV therapeutic programs

Scientists discover new links between inherited blindness and AHI1 gene

BARDA invites Aeolus Pharmaceuticals to submit proposal for development of AEOL 10150

NIH awards 12 research grants totaling $5 million for Tβ4 research

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Immune cells causes inflammation in thyroid-associated ophthalmopathy

Fibrocytes associated with Graves' disease

Scientists and clinicians address diagnosis and treatment for autoimmune and autoinflammatory diseases

CLSI’s document provides revised guidelines for screening cystic fibrosis

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

Excaliard Pharmaceuticals initiates Phase 2 trials of EXC 001

Increased coffee consumption linked to reduced hepatic fibrosis

Scientists develop mucus-penetrating biodegradable nanoparticles to deliver drugs over time

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News